

Using Metabolism to Attack Cancer

*Randall Riggs, President & CEO, Advanced Cancer Therapeutics
(www.advancedcancertherapeutics.com)*

The higher rate of glucose metabolism of cancer cells (the “Warburg effect”) is the basis for PET imaging and has been recognized as an important cancer target. Advanced Cancer Therapeutics is developing inhibitors of glycolysis targeting PFKFB3, a key enzyme of the glycolytic pathway that is over-expressed in a wide variety of solid tumors. Rational design of inhibitors of PFKFB3 resulted in small molecules that have both *in vitro* and *in vivo* compelling properties. Pre-clinical results will be presented showing pre-clinical candidates are well tolerated, orally bioavailable, and very efficacious in tumor models.